Assignee
ALLOGENE THERAPEUTICS INC
US·22 granted patents·29 pending applications·14 citations·filing 2015–2025
Top patents by PatentIndex Score
51 records- 0193US11673953B2DLL3 targeting chimeric antigen receptors and binding agentsALLOGENE THERAPEUTICS INC·Filed 2020·Granted Jun 13, 2023·9 cites·31 claims
- 0284US11072644B2Inhibitory chimeric antigen receptorsALLOGENE THERAPEUTICS INC·Filed 2015·Granted Jul 27, 2021·2 cites·21 claims
- 0379US12221462B2Methods and compositions for dosing of allogeneic chimeric antigen receptor T cellsALLOGENE THERAPEUTICS INC·Filed 2023·Granted Feb 11, 2025·2 cites·20 claims
- 0479US12036243B2BCMA CAR-T cells with enhanced activitiesALLOGENE THERAPEUTICS INC·Filed 2021·Granted Jul 16, 2024·1 cites·32 claims
- 0578US2024360196A1Inhibitory chimeric antigen receptorsALLOGENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0677US2024425839A1Modified caspase-9 polypeptides and methods of use thereofALLOGENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0776US12447178B2Method of treatment using anti-CD19 rituximab-resistant chimeric antigen receptorsALLOGENE THERAPEUTICS INC·Filed 2023·Granted Oct 21, 2025·0 cites·21 claims
- 0875US2025230410A1Chimeric antigen receptors with enhanced signaling and activities and uses thereofALLOGENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0974US12104188B2Modified caspase-9 polypeptides and methods of use thereofALLOGENE THERAPEUTICS INC·Filed 2022·Granted Oct 1, 2024·0 cites·35 claims
- 1072US2025171731A1Methods of manufacturing allogeneic car t cellsALLOGENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1172US2025051421A1Constitutively active chimeric cytokine receptorsALLOGENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1271US2026042857A1Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistenceALLOGENE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1370US12583905B2Methods and compositions for dosing of allogeneic chimeric antigen receptor T cellsALLOGENE THERAPEUTICS INC·Filed 2024·Granted Mar 24, 2026·0 cites·25 claims
- 1470US2024016846A1Chimeric cytokine receptors bearing a pd-1 ectodomainALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1569US2025207199A1Methods for detecting genomic abnormalities in cellsALLOGENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1668US12215347B2Chimeric antigen receptors with enhanced signaling and activities and uses thereofALLOGENE THERAPEUTICS INC·Filed 2021·Granted Feb 4, 2025·0 cites·12 claims
- 1768US11326156B2Modified caspase-9 polypeptides and methods of use thereofALLOGENE THERAPEUTICS INC·Filed 2018·Granted May 10, 2022·0 cites·17 claims
- 1867US2025333719A1Inducible chimeric cytokine receptorsALLOGENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1967US2022033462A1Inhibitory chimeric antigen receptorsALLOGENE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2066US2024101710A1B-cell maturation antigen (bcma) anti-idiotypic antibodiesALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2164US12295362B2Formulations and processes for CAR T cell drug productsALLOGENE THERAPEUTICS INC·Filed 2022·Granted May 13, 2025·0 cites·20 claims
- 2264US2024003056A1Anti-talen antibodies and uses thereofALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2363US2024228639A1Cd70 anti-idiotype antibodiesALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2462US12577290B2FasL expression and FasR gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell deathALLOGENE THERAPEUTICS INC·Filed 2022·Granted Mar 17, 2026·0 cites·22 claims
- 2562US2024216430A1Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereofALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2661US12404315B2Protease-activating CD45-gate CARALLOGENE THERAPEUTICS INC·Filed 2021·Granted Sep 2, 2025·0 cites·35 claims
- 2761US12043655B2Constitutively active chimeric cytokine receptorsALLOGENE THERAPEUTICS INC·Filed 2020·Granted Jul 23, 2024·0 cites·39 claims
- 2861US11896617B2Polynucleotides encoding rituximab-resistant chimeric antigen receptorsALLOGENE THERAPEUTICS INC·Filed 2020·Granted Feb 13, 2024·0 cites·23 claims
- 2961US11786553B2Chimeric cytokine receptors bearing a PD-1 ectodomainALLOGENE THERAPEUTICS INC·Filed 2020·Granted Oct 17, 2023·0 cites·33 claims
- 3061US2024042030A1Engineered cells with reduced gene expression to mitigate immune cell recognitionALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3161US2023407252A1Methods for donor cell analysisALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3260US12163153B2Methods of manufacturing allogeneic CAR T cellsALLOGENE THERAPEUTICS INC·Filed 2020·Granted Dec 10, 2024·0 cites·18 claims
- 3360US11781248B2Anti-TALEN antibodies and uses thereofALLOGENE THERAPEUTICS INC·Filed 2020·Granted Oct 10, 2023·0 cites·23 claims
- 3460US2022409665A1Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistenceALLOGENE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3559US12577283B2Knockdown or knockout of one or more of TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK to mitigate t cell recognition of allogeneic cell productsALLOGENE THERAPEUTICS INC·Filed 2022·Granted Mar 17, 2026·0 cites·39 claims
- 3659US2023346934A1Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signalsALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3758US2022184124A1Methods and reagents for characterizing car t cells for therapiesALLOGENE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3857US12365873B2Methods for transducing immune cellsALLOGENE THERAPEUTICS INC·Filed 2022·Granted Jul 22, 2025·0 cites·29 claims
- 3957US2025380684A1Formulations and processes for car t cell drug productsALLOGENE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4057US2024085403A1Method for inhibiting adventitious viral infectionALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4156US2026009000A1Methods for transducing immune cellsALLOGENE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4255US12163169B2Inducible chimeric cytokine receptorsALLOGENE THERAPEUTICS INC·Filed 2019·Granted Dec 10, 2024·0 cites·8 claims
- 4351US11732041B2Antibodies against 4G7-derived chimeric antigen receptorsALLOGENE THERAPEUTICS INC·Filed 2020·Granted Aug 22, 2023·0 cites·29 claims
- 4449US2019125799A1Methods and compositions for dosing of allogeneic chimeric antigen receptor t cellsALLOGENE THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4548US12528856B2Chimeric cytokine receptors comprising TGF β binding domainsALLOGENE THERAPEUTICS INC·Filed 2020·Granted Jan 20, 2026·0 cites·40 claims
- 4648US2021106498A1Plastic Jacket for Vial Labeling SystemsALLOGENE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4748US2020399343A1Improved t cell compositions and methodsALLOGENE THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4847US2023112444A1Combination therapies of chimeric antigen receptors targeting b-cell maturation antigen and gamma secretase inhibitorsALLOGENE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4944US2021062150A1Methods of preparing t cells for t cell therapyALLOGENE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 5043US2020261503A1Chimeric antigen receptors targeting b-cell maturation antigen and methods of use thereofALLOGENE THERAPEUTICS INC·Filed 2019·Application pending·0 cites
Showing the top 50 of 51 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →